01
The drug class that ate the endocrinology textbook, told one patient-year at a time.
- 01 How GLP-1 Medications Actually Work
- 02 Why GLP-1s Quiet Your Cravings
- 03 GLP-1s and Exercise: Better Together
Launch Edition
The Desks
A directory of the desks — the beats and the arguments in progress. Read in any order.
8 Active Desks
Desk of the Month
01
of 08
GLP-1
The decade of the drug that ate the endocrinology textbook.
What began as a type-2 diabetes injectable is now a cultural, economic and clinical phenomenon. Our GLP-1 desk covers the trial data, the prescribing questions, the muscle-and-bone debates, and the long tail of patients who are not in any trial at all.
Enter the GLP-1 Desk →We are writing about a drug class that is older than most of its patients' exposure to it, and younger than most of its unanswered questions. — Wellness Wire Editorial
This Week's Long Read
How GLP-1 Medications Actually Work
A plain-language look at what semaglutide, tirzepatide, and related drugs do inside the body, what the big trials showed, and where the science is still uncertain.
The Desks, Indexed
Everything we are covering, in order.
Nº · Desk · Three Pieces Updated continuously
02
Tirzepatide
Hot
The dual-agonist that is, on almost every measure, outperforming the monotherapy.
- 01 Tirzepatide vs. Semaglutide: What the Head-to-Head Evidence Says
- 02 Tirzepatide for Sleep Apnea: The SURMOUNT-OSA Results
03
The drug that made the category, and is now trying to hold its lane.
- 01 What the STEP Trials Showed About Semaglutide and Weight Loss
- 02 Oral vs. Injectable Semaglutide: How They Compare
04
The quiet, unglamorous layer of the market that most patients are actually on.
05
Peptides
Hot
The next-generation molecules — retatrutide, survodutide, BPC-157, and the names you will hear by 2027.
- 01 What 'Peptide Therapy' Actually Means
- 02 PT-141 (Bremelanotide): What the Evidence Shows
- 03 BPC-157: What the Human Evidence Actually Shows
06
The evidence, the grift, and the narrow strip of usefulness in between.
- 01 GLP-1s and Longevity: The Healthspan Question
- 02 Rapamycin and Longevity: What the Human Evidence Shows
- 03 NAD+ Boosters and Aging: What the Science Actually Says
07
Continuous glucose monitors, mitochondrial biomarkers, and the slow reframing of what "metabolic" means outside the diabetes clinic.
08
The platforms, the pharmacies, and the policy that shape how patients actually access these drugs.
- 01 How the GLP-1 Telehealth Boom Happened
- 02 Getting a GLP-1 Prescription Online: What to Know
- 03 The End of the GLP-1 Shortage — and What It Means
We add a desk when the beat earns it — meaning a story that doesn't fit anywhere else is showing up often enough to deserve its own editor. If you can see an argument we are missing, tell us.